The Value of BRAF VE1 Immunoexpression in Pediatric Langerhans Cell Histiocytosis

References

• Lo MCI, Paterson A, Maraka J, Clark R, Goodwill J, Nobes J, Garioch J, Moncrieff M, Rytina E, Igali L, et al. A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma. Br J Cancer. 2016;115(2):223–7. doi:10.1038/bjc.2016.106.
   PubMed Web of Science ®Google Scholar
• Ida CM, Vrana JA, Rodriguez FJ, Jentoft ME, Caron AA, Jenkins SM, Giannini C. Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma. Acta Neuropathol Commun. 2013;1:20 doi:10.1186/2051-5960-1-20.
   PubMed Web of Science ®Google Scholar
• Tosuner Z, Geçer MÖ, Hatiboğlu MA, Abdallah A, Turna S. BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma. Oncol Lett. 2018;16(2):2402–8. doi:10.3892/ol.2018.8919.
   PubMed Web of Science ®Google Scholar
• Sasaki H, Shimizu S, Tani Y, Shitara M, Okuda K, Hikosaka Y, Moriyama S, Yano M, Fujii Y. Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in Japanese lung adenocarcinoma. Lung Cancer. 2013;82(1):51–4. doi:10.1016/j.lungcan.2013.06.014.
   PubMed Web of Science ®Google Scholar
• Badalian-Very G, Vergilio J-A, Degar BA, MacConaill LE, Brandner B, Calicchio ML, Kuo FC, Ligon AH, Stevenson KE, Kehoe SM, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919–23. doi:10.1182/blood-2010-04-279083.
   PubMed Web of Science ®Google Scholar
• Berres M-L, Lim KPH, Peters T, Price J, Takizawa H, Salmon H, Idoyaga J, Ruzo A, Lupo PJ, Hicks MJ, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2015;212(2):281 doi:10.1084/jem.2013097701202015c.
   PubMed Web of Science ®Google Scholar
• Héritier S, Emile J-F, Barkaoui M-A, Thomas C, Fraitag S, Boudjemaa S, Renaud F, Moreau A, Peuchmaur M, Chassagne-Clément C, et al. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy. JCO. 2016;34(25):3023–30. doi:10.1200/JCO.2015.65.9508.
   PubMed Web of Science ®Google Scholar
• Kim J-k, Seong CY, Bae IE, Yi JW, Yu HW, Kim S-j, Won J-K, Chai YJ, Choi JY, Lee KE, et al. Comparison of Immunohistochemistry and Direct Sequencing Methods for Identification of the BRAFV600E Mutation in Papillary Thyroid Carcinoma. Ann Surg Oncol. 2018;25(6):1775–81. doi:10.1245/s10434-018-6460-3.
   PubMed Web of Science ®Google Scholar
• Zhu X, Luo Y, Bai Q, Lu Y, Lu Y, Wu L, Zhou X. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma. Exp Mol Pathol. 2016;100(1):236–41. doi:10.1016/j.yexmp.2016.01.004.
   PubMed Web of Science ®Google Scholar
• Dvorak K, Higgins A, Palting J, Cohen M, Brunhoeber P. Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review. Pathol Oncol Res. 2019;25(1):349–59. doi:10.1007/s12253-017-0344-x.
   PubMed Web of Science ®Google Scholar
• Bösmüller H, Fischer A, Pham DL, Fehm T, Capper D, von Deimling A, Bonzheim I, Staebler A, Fend F. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. Hum Pathol. 2013;44(3):329–35. doi:10.1016/j.humpath.2012.07.010.
   PubMed Web of Science ®Google Scholar
• Routhier CA, Mochel MC, Lynch K, Dias-Santagata D, Louis DN, Hoang MP. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas. Hum Pathol. 2013;44(11):2563–70. doi:10.1016/j.humpath.2013.06.018.
   PubMed Web of Science ®Google Scholar
• Cantwell-Dorris ER, O'Leary JJ, Sheils OM. BRAFV600E: Implications for Carcinogenesis and Molecular Therapy. Mol Cancer Ther. 2011;10(3):385–94. doi:10.1158/1535-7163.MCT-10-0799.
   PubMed Web of Science ®Google Scholar
• Lau SK, Chu PG, Weiss LM. Immunohistochemical Expression of Langerin in Langerhans Cell Histiocytosis and Non-Langerhans Cell Histiocytic Disorders. Am J Surg Pathol. 2008;32(4):615–9. doi:10.1097/PAS.0b013e31815b212b.
   PubMed Web of Science ®Google Scholar
• Emile J-F, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, Requena-Caballero L, Jordan MB, Abdel-Wahab O, Allen CE, Histiocyte Society, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127(22):2672–81. doi:10.1182/blood-2016-01-690636.
   PubMed Web of Science ®Google Scholar
• Birbeck MS, Breathnach AS, Everall JD. An electron microscope study of basal melanocytes and high-level clear cells (Langerhans cell) in vitiligo. J Invest Dermatol. 1961;37(1):51–64. doi:10.1038/jid.1961.80.
   Web of Science ®Google Scholar
• Gadner H, Minkov M, Grois N, Pötschger U, Thiem E, Aricò M, Astigarraga I, Braier J, Donadieu J, Henter J-I, et al. Histiocyte Society. Therapy prolongation improved outcome in multisystem Langerhans cell histiocytosis. Blood. 2013;121(25):5006–14. doi:10.1182/blood-2012-09-455774.
   PubMed Web of Science ®Google Scholar
• Hicks J, Flaitz CM. Langerhans cell histiocytosis: Current insights in a molecular age with emphasis on clinical oral and maxillofacial pathology practice. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100(2 Suppl):S42–S66. doi:10.1016/j.tripleo.2005.06.016.
   PubMed Web of Science ®Google Scholar
• Simko SJ, Garmezy B, Abhyankar H, Lupo PJ, Chakraborty R, Lim KPH, Shih A, Hicks MJ, Wright TS, Levy ML, et al. Differentiating Skin-Limited and Multisystem Langerhans Cell Histiocytosis. J Pediatr. 2014;165(5):990–6. doi:10.1016/j.jpeds.2014.07.063.
   PubMed Web of Science ®Google Scholar
• Ilie MI, Lassalle S, Long-Mira E, Bonnetaud C, Bordone O, Lespinet V, Lamy A, Sabourin J-C, Haudebourg J, Butori C, et al. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays. Thyroid. 2014;24(5):858–66. doi:10.1089/thy.2013.0302.
   PubMed Web of Science ®Google Scholar
• Parker KG, White MG, Cipriani NA. Comparison of molecular methods and BRAF Immunohistochemistry (VE1 Clone) for the detection of BRAF V600E mutation in papillary thyroid carcinoma: a meta-analysis. Head Neck Pathol. 2020
   PubMed Web of Science ®Google Scholar
• Choden S, Keelawat S, Jung CK, Bychkov A. VE1 Immunohistochemistry improves the limit of genotyping for detecting BRAFV600E mutation in papillary thyroid cancer. Cancers. 2020;12(3):596. doi:10.3390/cancers12030596.
   PubMed Web of Science ®Google Scholar
• Anwar MAF, Murad F, Dawson E, Abd Elmageed ZY, Tsumagari K, Kandil E. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature. J Surg Res. 2016;203(2):407–15. doi:10.1016/j.jss.2016.04.029.
   PubMed Web of Science ®Google Scholar
• Pyo JS, Sohn JH, Kang G. BRAF Immunohistochemistry Using Clone VE1 is Strongly Concordant with BRAF(V600E) Mutation Test in Papillary Thyroid Carcinoma. Endocr Pathol. 2015;26(3):211–7. doi:10.1007/s12022-015-9374-7.
   PubMed Web of Science ®Google Scholar
• Dvorak K, Aggeler B, Palting J, McKelvie P, Ruszkiewicz A, Waring P. Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma. Pathology. 2014;46(6):509–17. doi:10.1097/PAT.0000000000000119.
   PubMed Web of Science ®Google Scholar
• Ballester LY, Cantu MD, Lim KPH, Sarabia SF, Ferguson LS, Renee Webb C, Allen CE, McClain KL, Mohila CA, Punia JN, et al. The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis . Hematol Oncol. 2018;36(1):307–15. doi:10.1002/hon.2388.
   PubMed Web of Science ®Google Scholar
• Roden AC, Hu X, Kip S, Parrilla Castellar ER, Rumilla KM, Vrana JA, Vassallo R, Ryu JH, Yi ES. BRAF V600E expression in Langerhans cell histiocytosis: clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases. Am J Surg Pathol. 2014;38(4):548–51. doi:10.1097/PAS.0000000000000129.
   PubMed Web of Science ®Google Scholar
• Satoh T, Smith A, Sarde A, Lu H-c, Mian S, Mian S, Trouillet C, Mufti G, Emile J-F, Fraternali F, et al. B-RAF Mutant alleles associated with langerhans cell histiocytosis, a granulomatous pediatric disease. PLoS ONE. 2012;7(4):e33891 doi:10.1371/journal.pone.0033891.
   PubMed Web of Science ®Google Scholar
• Haroche J, Charlotte F, Arnaud L, von Deimling A, Hélias-Rodzewicz Z, Hervier B, Cohen-Aubart F, Launay D, Lesot A, Mokhtari K, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120(13):2700–3. doi:10.1182/blood-2012-05-430140.
   PubMed Web of Science ®Google Scholar
• Go H, Jeon YK, Huh J, Choi SJ, Choi Y-D, Cha HJ, Kim H-J, Park G, Min S, Kim JE, et al. Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms. Histopathology. 2014;65(2):261–72. doi:10.1111/his.12416.
   PubMed Web of Science ®Google Scholar
• Ozer E, Sevinc A, Ince D, Yuzuguldu R, Olgun N. BRAF V600E mutation: a significant biomarker for prediction of disease relapse in pediatric langerhans cell histiocytosis. Pediatr Dev Pathol. 2019;22(5):449–55. doi:10.1177/1093526619847859.
   PubMed Web of Science ®Google Scholar
• Ritterhouse LL, Barletta JA. BRAF V600E mutation-specific antibody: a review. Semin Diagn Pathol. 2015;32(5):400–8. doi:10.1053/j.semdp.2015.02.010.
   PubMed Web of Science ®Google Scholar
• Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, Pusch S, Mechtersheimer G, Zentgraf H, von Deimling A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011;122(1):11–9. doi:10.1007/s00401-011-0841-z.
   PubMed Web of Science ®Google Scholar
• Méhes G, Irsai G, Bedekovics J, Beke L, Fazakas F, Rózsa T, Kiss C. Activating BRAF V600E mutation in aggressive pediatric langerhans cell histiocytosis: demonstration by allele-specific PCR/direct sequencing and immunohistochemistry. Am J Surg Pathol. 2014;38(12):1644–8. doi:10.1097/PAS.0000000000000304.
   PubMed Web of Science ®Google Scholar
• Gow C-H, Hsieh M-S, Lin Y-T, Liu Y-N, Shih J-Y. Validation of immunohistochemistry for the detection of BRAF V600E-mutated lung adenocarcinomas. Cancers. 2019;11(6):866. doi:10.3390/cancers11060866.
   Web of Science ®Google Scholar